$BIAF
bioAffinity Technologies, Inc. Stock $biaf

$biaf Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224012358 Filed on April 01, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$2.406M	$2.213M	$7.900M
YoY Change	261180.24%	94085.53%	164380.53%
Cost Of Revenue	$1.573M	$1.665M	$1.741M
YoY Change	1808451.72%	924822.22%	372679.44%
Gross Profit	$833.0K	$548.5K	$791.6K
YoY Change	99774.1%	25176.5%	18156.92%
Gross Profit Margin	34.61%	24.78%	10.02%
Selling, General & Admin	$2.186M	$2.214M	$6.791M
YoY Change	86.9%	54.97%	149.01%
% of Gross Profit	262.43%	403.64%	857.82%
Research & Development	$393.6K	$528.2K	$1.500M
YoY Change	6.5%	167.77%	36.36%
% of Gross Profit	47.26%	96.29%	189.48%
Depreciation & Amortization	$38.81K	$149.6K	$233.1K
YoY Change	76.41%	1940.79%	2189.43%
% of Gross Profit	4.66%	27.27%	29.44%
Operating Expenses	$4.352M	$2.891M	$10.51M
YoY Change	179.16%	77.8%	161.64%
Operating Profit	-$1.945M	-$2.342M	-$7.973M
YoY Change	24.86%	44.26%	98.78%
Interest Expense	$23.55K	-$13.16K	$37.13K
YoY Change	-36.35%	-74.11%	-98.53%
% of Operating Profit
Other Income/Expense, Net	-$12.91K	-$15.30K	$57.21K
YoY Change	-134.9%		-101.38%
Pretax Income	-$1.958M	-$2.371M	-$7.916M
YoY Change	28.74%	41.58%	-2.89%
Income Tax	$3.672K	$2.290K	$20.99K
% Of Pretax Income
Net Earnings	-$1.962M	-$2.373M	-$7.937M
YoY Change	27.99%	41.72%	-2.66%
Net Earnings / Revenue	-81.53%	-107.22%	-100.47%
Basic Earnings Per Share	-$0.20		-$0.91
Diluted Earnings Per Share	-$0.20	-$0.25	-$0.91
COMMON SHARES
Basic Shares Outstanding	11.51M shares	9.502M shares	8.748M shares
Diluted Shares Outstanding	9.915M shares		8.748M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.453M	$2.822M	$2.822M
YoY Change	-74.89%	-75.28%	-75.28%
Cash & Equivalents	$2.500M	$2.800M	$2.822M
Short-Term Investments
Other Short-Term Assets	$344.9K	$321.0K	$321.0K
YoY Change	-21.81%	-39.65%	-39.65%
Inventory	$9.487K	$18.48K	$18.48K
Prepaid Expenses
Receivables	$1.124M	$811.7K	$811.7K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$3.931M	$3.973M	$3.973M
YoY Change	-61.58%	-66.79%	-66.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$461.2K	$458.6K	$1.995M
YoY Change	104.92%	113.88%	830.23%
Goodwill	$1.404M	$1.404M
YoY Change
Intangibles	$818.9K	$833.5K
YoY Change
Long-Term Investments
YoY Change
Other Assets	$16.06K	$16.06K	$849.5K
YoY Change	132.08%	167.67%	14058.83%
Total Long-Term Assets	$4.118M	$4.249M	$4.249M
YoY Change	1675.14%	1827.44%	1827.42%
TOTAL ASSETS
Total Short-Term Assets	$3.931M	$3.973M	$3.973M
Total Long-Term Assets	$4.118M	$4.249M	$4.249M
Total Assets	$8.049M	$8.222M	$8.222M
YoY Change	-23.08%	-32.51%	-32.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$384.0K	$604.8K	$604.8K
YoY Change	162.05%	75.28%	75.28%
Accrued Expenses	$883.3K	$1.150M	$1.245M
YoY Change	83.51%	112.18%	129.66%
Deferred Revenue
YoY Change
Short-Term Debt	$4.690K	$0.00	$0.00
YoY Change	-97.22%	-100.0%	-100.0%
Long-Term Debt Due	$372.8K	$365.5K	$365.5K
YoY Change
Total Short-Term Liabilities	$1.772M	$2.248M	$2.248M
YoY Change	122.48%	97.41%	97.41%
LONG-TERM LIABILITIES
Long-Term Debt	$762.5K	$835.5K	$835.5K
YoY Change
Other Long-Term Liabilities	$258.1K	$283.0K	$283.0K
YoY Change
Total Long-Term Liabilities	$1.021M	$1.118M	$1.118M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.772M	$2.248M	$2.248M
Total Long-Term Liabilities	$1.021M	$1.118M	$1.118M
Total Liabilities	$2.792M	$3.366M	$3.366M
YoY Change	250.65%	195.63%	195.63%
SHAREHOLDERS EQUITY
Retained Earnings	-$46.60M	-$44.60M
YoY Change	21.99%	21.53%
Common Stock	$78.52K	$65.76K
YoY Change	32.53%	12.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.257M	$4.855M	$4.855M
YoY Change
Total Liabilities & Shareholders Equity	$8.049M	$8.222M	$8.222M
YoY Change	-23.08%	-32.51%	-32.51%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$1.962M	-$2.373M	-$7.937M
YoY Change	27.99%	41.72%	-2.66%
Depreciation, Depletion And Amortization	$38.81K	$149.6K	$233.1K
YoY Change	76.41%	1940.79%	2189.43%
Cash From Operating Activities	-$2.346M	-$1.618M	-$6.038M
YoY Change	53.43%	24.39%	48.32%
INVESTING ACTIVITIES
Capital Expenditures	$41.39K	-$17.10K	$22.90K
YoY Change	28.08%	-107.77%	-89.59%
Acquisitions			$2.186M
YoY Change
Other Investing Activities		$3.500K	-$2.187M
YoY Change
Cash From Investing Activities	-$41.39K	$10.60K	-$2.209M
YoY Change	28.08%	-104.82%	904.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$2.019M	-84.98K	-$345.0K
YoY Change	-2523.25%	-84.92%	-102.41%
NET CHANGE
Cash From Operating Activities	-$2.346M	-1.618M	-$6.038M
Cash From Investing Activities	-$41.39K	10.60K	-$2.209M
Cash From Financing Activities	$2.019M	-84.98K	-$345.0K
Net Change In Cash	-$368.4K	-1.692M	-$8.592M
YoY Change	-77.6%	-18.81%	-185.47%
FREE CASH FLOW
Cash From Operating Activities	-$2.346M	-$1.618M	-$6.038M
Capital Expenditures	$41.39K	-$17.10K	$22.90K
Free Cash Flow	-$2.387M	-$1.601M	-$6.061M
YoY Change	52.9%	5.27%	41.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset		usd
CY2022Q4	us-gaap	Goodwill Goodwill		usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill		usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent		usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent		usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent		usd
CY2023Q4	us-gaap	Loans Payable Current LoansPayableCurrent		usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
CY2022	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense		usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023	BIAF	Fair Value Adjustments On Convertible Notes Payable FairValueAdjustmentsOnConvertibleNotesPayable		usd
CY2023	us-gaap	Accretion Expense AccretionExpense		usd
CY2023	BIAF	Fair Value Adjustments On Convertible Notes Payable FairValueAdjustmentsOnConvertibleNotesPayable		usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue		usd
CY2023	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet		usd
CY2022	BIAF	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset		usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
CY2023	BIAF	Payment On Loans Payable PaymentOnLoansPayable		usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2023	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2023	BIAF	Payment Of Return Of Capital From Stock Split PaymentOfReturnOfCapitalFromStockSplit		usd
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts		usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments		usd
CY2022	us-gaap	Stock Issued1 StockIssued1		usd
CY2023	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		usd
CY2023	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1		usd
CY2023	BIAF	Fair Value Of Warrants Issued FairValueOfWarrantsIssued		usd
CY2023	BIAF	Beneficial Conversion Feature For Bridge Notes BeneficialConversionFeatureForBridgeNotes		usd
CY2022Q4	BIAF	Patient Service Fees PatientServiceFees		usd
CY2022Q4	BIAF	Histology Fees HistologyFees		usd
CY2022Q4	BIAF	Medical Director Fees MedicalDirectorFees		usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization		usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense		usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost		usd
CY2022	us-gaap	Lease Cost LeaseCost		usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent		usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability		usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization		usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset		usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent		usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent		usd
CY2022Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability		usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent		pure
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent		pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2022Q4	BIAF	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities		usd
CY2022Q4	BIAF	Deferred Tax Liability Rightofuse Asset DeferredTaxLiabilityRightofuseAsset		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	14000000.0	usd
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Name AuditorName	WithumSmith+Brown, PC
CY2023	dei	Auditor Location AuditorLocation	New York, New York
CY2023	dei	Auditor Firm AuditorFirmId	100
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2821570	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11413759	usd
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	811674	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	10489	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	18484	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	5540	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	321017	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	531899	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	3972745	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	11961687	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	458633	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	214438	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	370312	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	1165844	usd
CY2023Q4	us-gaap	Goodwill Goodwill	1404486	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	833472	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	16060	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6000	usd
CY2023Q4	us-gaap	Assets Assets	8221552	usd
CY2022Q4	us-gaap	Assets Assets	12182125	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	604789	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	345042	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1149811	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	541894	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	33058	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	94708	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	365463	usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	251746	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2247829	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1138682	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	283001	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	835467	usd
CY2023Q4	us-gaap	Liabilities Liabilities	3366297	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1138682	usd
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9394610	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9394610	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8381324	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8381324	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	65762	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	58669	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	49393972	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	47652242	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-44604479	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-36667468	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4855255	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11043443	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8221552	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12182125	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4803	usd
CY2023	BIAF	Direct Costs And Expenses DirectCostsAndExpenses	1740884	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1467936	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1378624	usd
CY2023	BIAF	Clinical Development Expense ClinicalDevelopmentExpense	256661	usd
CY2022	BIAF	Clinical Development Expense ClinicalDevelopmentExpense	145546	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6790654	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2481042	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	249592	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	10182	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	10505727	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	4015861	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-7973228	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-4011058	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	122131	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	46708	usd
CY2023	us-gaap	Interest Expense InterestExpense	37125	usd
CY2022	us-gaap	Interest Expense InterestExpense	2532640	usd
CY2023	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	3325	usd
CY2023	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	31121	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	212258	usd
CY2022	BIAF	Fair Value Adjustments On Convertible Notes Payable FairValueAdjustmentsOnConvertibleNotesPayable	-1866922	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7916018	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8151654	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	20993	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2459	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7937011	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8154113	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.91
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.91
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.81
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.81
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8747509	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8747509	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4498964	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4498964	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-15790719	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	248592	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	462344	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	-185	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	352250	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1800000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6027414	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	4044318	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	16065332	usd
CY2022	BIAF	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	7713310	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	74900	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8154113	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11043443	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	748823	usd
CY2023	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1000000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7937011	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4855255	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7937011	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8154113	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	249592	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	10182	usd
CY2022	us-gaap	Accretion Expense AccretionExpense	2055627	usd
CY2022	BIAF	Fair Value Adjustments On Convertible Notes Payable FairValueAdjustmentsOnConvertibleNotesPayable	-1866922	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	748823	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	248592	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	212258	usd
CY2023	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-311366	usd
CY2022	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	8959	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	12944	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5540	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-214402	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	492753	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-14501	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	114635	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	362012	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	66335	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	33058	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	440485	usd
CY2023	BIAF	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-7397	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6037806	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4070845	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	22902	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	219987	usd
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	2186497	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2209399	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-219987	usd
CY2023	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	-251746	usd
CY2022	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	555148	usd
CY2022	BIAF	Payment On Loans Payable PaymentOnLoansPayable	269983	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	724000	usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	425000	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1800000	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	6027414	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	7713310	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	74900	usd
CY2022	BIAF	Payment Of Return Of Capital From Stock Split PaymentOfReturnOfCapitalFromStockSplit	185	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	55651	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	93238	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-344984	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14343953	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8592189	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	10053121	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11413759	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1360638	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2821570	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11413759	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	20993	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	30637	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	37125	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	2459	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	1000000	usd
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	4044318	usd
CY2022	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	16065332	usd
CY2022	BIAF	Fair Value Of Warrants Issued FairValueOfWarrantsIssued	352250	usd
CY2022	BIAF	Beneficial Conversion Feature For Bridge Notes BeneficialConversionFeatureForBridgeNotes	462344	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-44600000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2800000	usd
CY2023Q4	BIAF	Total Assets Percent TotalAssetsPercent	0.34	pure
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_zcp03MqekjXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zm9wG7oq1Nhf">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the valuation allowance on the Company’s deferred tax assets, stock-based compensation, valuation of goodwill and intangible assets related to the business combination, allowance for contractual adjustments and discounts related to service revenues, and the useful lives of fixed assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Revenues Revenues	7900000	usd
CY2022	us-gaap	Revenues Revenues	6900000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	8600000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	8600000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.99
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.91
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zXLUdq2V42e7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zsnbU3hMHAB1">Concentration of Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $<span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20231231_z1UGfHhZcwl4" title="Federal insured limit">250,000</span>. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023	us-gaap	Advertising Expense AdvertisingExpense	89000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	39000	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5333647	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5456344	shares
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2532499	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4803	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	57210	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4140596	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7916018	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8151654	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84E_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zNCkflN2BHoe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zQnWsrDGJSZi">Reclassifications</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year balances have been reclassified to conform to current year presentation. The Company reclassified legal fees and annuity costs relating to patents of approximately $<span id="xdx_90F_ecustom--ReclassifiedPatentExpensesAndAnnuityCosts_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember__srt--RestatementAxis__srt--RestatementAdjustmentMember_zh267PXTQbQ2" title="Reclassified patent expenses and annuity costs">236,000</span> from research and development to selling, general and administrative for the year ended December 31, 2022, respectively, as these expenses are not deemed research and development.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2254486	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-16528	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2237958	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	16528	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2532499	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4803	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-7973228	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-4011058	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	20993	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2459	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7937011	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8154113	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1500000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1400000	usd
CY2023Q4	BIAF	Patient Service Fees PatientServiceFees	657717	usd
CY2023Q4	BIAF	Histology Fees HistologyFees	121301	usd
CY2023Q4	BIAF	Medical Director Fees MedicalDirectorFees	3103	usd
CY2023Q4	us-gaap	Other Receivables OtherReceivables	29553	usd
CY2022Q4	us-gaap	Other Receivables OtherReceivables	10489	usd
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	811674	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	10489	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	171855	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	340078	usd
CY2023Q4	BIAF	Prepaid Legal And Professional PrepaidLegalAndProfessional	24476	usd
CY2022Q4	BIAF	Prepaid Legal And Professional PrepaidLegalAndProfessional	72048	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	124686	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	119773	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	321017	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	531899	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	831756	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	483618	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	373123	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	269180	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	458633	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	214438	usd
CY2023	us-gaap	Depreciation Depreciation	233064	usd
CY2022	us-gaap	Depreciation Depreciation	10182	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	857037	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	340680	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	257926	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	144440	usd
CY2023Q4	BIAF	Accrued Clinical Expense Current AccruedClinicalExpenseCurrent	15350	usd
CY2022Q4	BIAF	Accrued Clinical Expense Current AccruedClinicalExpenseCurrent	50922	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	19498	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5852	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1149811	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	541894	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	33058	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P3Y6M29D
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	128324	usd
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	33838	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	39887	usd
CY2023	us-gaap	Lease Cost LeaseCost	202049	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	370312	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	94708	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	283001	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	377709	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	1294168	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	128324	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	1165844	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	365463	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	835467	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	1200930	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y6M29D
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0807	pure
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0801	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	121726	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	448505	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	121726	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	448505	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	121726	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	270395	usd
CY2023Q4	BIAF	Lessee Operating Lease Liability Payments Due Year Four And Thereafter LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereafter	71007	usd
CY2023Q4	BIAF	Finance Lease Liability Payments Due Year Four And Thereafter FinanceLeaseLiabilityPaymentsDueYearFourAndThereafter	202970	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	436185	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	1370375	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	58476	usd
CY2023Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	169445	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	377709	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	1200930	usd
CY2023	us-gaap	Payments For Rent PaymentsForRent	112124	usd
CY2022	us-gaap	Payments For Rent PaymentsForRent	65043	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.007
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	14285715	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2022Q4	BIAF	Common Stock Shares Issued Including Unvested Restricted Stock CommonStockSharesIssuedIncludingUnvestedRestrictedStock	9505255	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8381324	shares
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	748823	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	248592	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	322	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	7142	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.84
CY2022Q4	us-gaap	Share Price SharePrice	4.62
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.639	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0220	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4649952	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4649952	shares
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	30000000	usd
CY2023	BIAF	Effective Income Tax Rate Reconciliation In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationInDeferredTaxAssetsValuationAllowance	1	pure
CY2023Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	3000000.0	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	800000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6479696	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3871192	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	325320	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	477055	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	525463	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	260560	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	204013	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	5708	usd
CY2023Q4	BIAF	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	79319	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	582206	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	443867	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	8196018	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	5058382	usd
CY2023Q4	BIAF	Deferred Tax Liability Rightofuse Asset DeferredTaxLiabilityRightofuseAsset	77766	usd
CY2023Q4	BIAF	Deferred Tax Liability Depreciation And Amortization DeferredTaxLiabilityDepreciationAndAmortization	59248	usd
CY2022Q4	BIAF	Deferred Tax Liability Depreciation And Amortization DeferredTaxLiabilityDepreciationAndAmortization	7337	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	137014	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	7337	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8059004	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5051045	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.0003	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.1040	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.0083	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.0220	pure
CY2023	BIAF	Effective Income Tax Rate Reconciliation Deferred Balance True Up EffectiveIncomeTaxRateReconciliationDeferredBalanceTrueUp	0.1607	pure
CY2022	BIAF	Effective Income Tax Rate Reconciliation Deferred Balance True Up EffectiveIncomeTaxRateReconciliationDeferredBalanceTrueUp	0.0000	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.3787	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.1010	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000	pure
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	249517	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	190229	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	190229	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	49646	usd
CY2023	BIAF	Unrecognized Tax Benefits Increase Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreasesResultingFromPriorPeriodTaxPositions	30897	usd
CY2022	BIAF	Unrecognized Tax Benefits Increase Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreasesResultingFromPriorPeriodTaxPositions	110681	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	28391	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	29902	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	249517	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	190229	usd

Files In Submission

Name	View Source	Status
0001493152-24-012358-index-headers.html	Edgar Link	pending
0001493152-24-012358-index.html	Edgar Link	pending
0001493152-24-012358.txt	Edgar Link	pending
0001493152-24-012358-xbrl.zip	Edgar Link	pending
biaf-20231231.xsd	Edgar Link	pending
ex19-1.htm	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex3-1.htm	Edgar Link	pending
ex3-3.htm	Edgar Link	pending
ex3-5.htm	Edgar Link	pending
biaf-20231231_cal.xml	Edgar Link	unprocessable
biaf-20231231_def.xml	Edgar Link	unprocessable
biaf-20231231_lab.xml	Edgar Link	unprocessable
biaf-20231231_pre.xml	Edgar Link	unprocessable
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex4-13.htm	Edgar Link	pending
ex97-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
form10-k_htm.xml	Edgar Link	completed
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BIAF
bioAffinity Technologies, Inc. Stock $biaf

2024 Q1 Form 10-K Financial Statement

#000149315224012358 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIAF bioAffinity Technologies, Inc. Stock $biaf

2024 Q1 Form 10-K Financial Statement

#000149315224012358 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIAF
bioAffinity Technologies, Inc. Stock $biaf